Nicolas Delarche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicolas Delarche has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Abdourahmane Diallo
Unité de Recherche Clinique, Hôpital Fernand Widal, APHP, Université Paris-Diderot Paris 7, 75010 Paris, France
1 shared publication - Anne Bellemain-Appaix
Centre Hospitalier d’Antibes – Juan-les-Pins, Antibes, France (A.-B.A.).
1 shared publication - Christophe Caussin
Institut Mutualiste Montsouris (IMM), Paris, France (C.C.).
1 shared publication - David Attias
Centre cardiologique du Nord, 93200 Saint-Denis, France
1 shared publication - Emile Ferrari
CHU Nice, Université Côte d’Azur, Nice, France (E.F.).
1 shared publication - Eric Vicaut
AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7
1 shared publication
Latest Publications
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.